yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
Red Hat
The Opening of Virtualization
User Environment Management – The Third Layer of the Desktop
Cloud Computing for Business Agility
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Return on Assests: Bringing Visibility to your SOA Strategy
Managing Hybrid Endpoint Environments
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
How Can AJAX Improve Homeland Security?
Beyond Widgets: What a RIA Platform Should Offer
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
Top Links You Must Click On

DRI Capital Celebrates 20 Years of Healthcare Royalty Investing

TORONTO, Jan. 6, 2013 /PRNewswire/ -- DRI Capital ("DRI"), a pioneer in the global field of pharmaceutical royalty monetization, is pleased to announce the completion of over $600 million in transactions for 2012. Formerly known as Drug Royalty Corporation, DRI is celebrating its 20th anniversary in 2013. As the original firm to monetize pharmaceutical royalties, DRI and its managed funds have been instrumental in helping to create the robust and liquid market for the recipients of royalties on healthcare related products that exists today.

Over the past 20 years DRI has worked with more healthcare royalty recipients than any other royalty monetization firm, and its managed funds have completed the most royalty transactions and purchased the most royalty entitlements. DRI's Drug Royalty funds currently hold what DRI believes to be the most diversified portfolio of healthcare royalty entitlements in the industry today. In building this portfolio, DRI led the way with numerous milestone transactions, including the first transaction outside the United States, the first transaction with an individual inventor, the first transaction on a diagnostic, the first transaction on a life science tool and the first transaction involving a bundle of royalty streams. Further, DRI's managed funds have completed more repeat transactions with prior counterparties than any other, reinforcing DRI's leading reputation in the industry.

2012 marked a banner year for DRI with its Drug Royalty II and managed funds committing over $600 million while purchasing six individual royalty entitlements, each on medically necessary, market leading products. In 2012 DRI's funds continued to lead the evolution of royalty monetization by completing the first ARTS™ structured investment. This novel structure innovated by DRI enables life sciences companies to accelerate payments by selling their long-term royalty and related rights in exchange for larger payments over a shorter period.

"Over the past 20 years it has been a privilege to work with some of the world's leading academic institutions, pharmaceutical & biotechnology companies and individual inventors. We value the many relationships we have formed in the life sciences community over the years and are excited to see the proceeds of these transactions continue to advance science," said Behzad Khosrowshahi, President and CEO of DRI. "We saw our most robust year in 2012 in terms of capital allocated, and our managed funds will continue to provide capital to royalty recipients. Based on our current pipeline and what we are seeing in the market today, we believe 2013 will be another groundbreaking year."

DRI will be attending the J.P. Morgan Healthcare Conference from January 7th to 10th, 2013 and the AUTM Annual Meeting from February 27th to March 2nd, 2013. 

About DRI Capital

Based in Toronto, Canada, DRI Capital Inc. (formerly Drug Royalty Corporation Inc.) is a life sciences industry-focused investment management firm with approximately US$2 billion under management that acquires royalties from universities, inventors, research institutes and pharmaceutical and biotechnology companies. DRI Capital-managed funds have completed 20 royalty transactions over the past two and a half years. Royalties recently acquired by DRI Capital's managed funds include those on Johnson and Johnson's REMICADE®, Amgen and Pfizer's ENBREL® and Biogen Idec and Elan's TYSABRI®. Additional information about DRI Capital is available at

DRI Capital Contact:
Jeff Pootoolal
(416) 562-8911


About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Enterprise Open Source Magazine Latest Stories . . .
Using any programming framework to the fullest extent possible first requires an understanding of advanced software architecture concepts. While writing a little client-side JavaScript does not necessarily require as much consideration when designing a scalable software architecture, t...
Test-driven development (TDD) has been around for a while now. Behavior-driven development (BDD), a comparably recent methodology, emerged from the practice of TDD and could reasonably be called a narrower application of TDD. The TDD process allows a developer to use a failing unit t...
Developers generally like to share their code, and many of them do so by open sourcing it on GitHub, a social code hosting and collaboration service. Many companies also use GitHub as a convenient place to host both private and public code repositories by creating GitHub organizations ...
It is no surprise that OpenStack has evolved into a widely adopted cloud management framework. As it hurtles on a trajectory of rapid growth, a new breed of demands are making themselves felt – demands that a mature platform of this nature and scope must satisfy. One such requirement i...
The combined notions of open source and the ‘community contribution’ model of collaborative software application development are, of course, not new. The history of open source is actually traced back to early software exchanges between universities driven by academic principles of kn...
Cloud computing delivers on-demand IT resources that provide businesses flexibility. The challenge is the cost and complexity of cloud security compliance (PCI, HIPAA, FFIEC). Raxak Protect automated cloud security enables cloud apps to be deployed quickly and cost-effectively. Get the...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers